All In Biotech

Drug Trial Radar · NCT06866236

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Oct 2025

Primary completion

Oct 2026

Study completion Jul 2027

Sponsor

Lead sponsor
Ebima Clifford OkundayeIndustry
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Conditions

  • Chronic Kidney Diseases
  • Acute Kidney Injury
  • Kidney Failure

Interventions

  • QRX-3Drug

    capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in Glomerular filtration rateTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neukidney Inc

    Pasedena, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.